Last reviewed · How we verify
Injection Sclerotherapy
Injection sclerotherapy works by injecting a sclerosing agent directly into abnormal blood vessels or varicose veins to cause inflammation, fibrosis, and obliteration of the vessel.
Injection sclerotherapy works by injecting a sclerosing agent directly into abnormal blood vessels or varicose veins to cause inflammation, fibrosis, and obliteration of the vessel. Used for Varicose veins, Spider veins (telangiectasia), Venous malformations.
At a glance
| Generic name | Injection Sclerotherapy |
|---|---|
| Also known as | 5% ethanolamine oleate, Sotradecol |
| Sponsor | Gulab Devi Hospital |
| Drug class | Sclerosing agent |
| Modality | Small molecule |
| Therapeutic area | Vascular/Dermatology |
| Phase | Phase 3 |
Mechanism of action
The sclerosing agent (typically sodium tetradecyl sulfate, polidocanol, or similar) damages the endothelial lining of the target vessel, triggering an inflammatory response that leads to fibrosis and eventual closure. The vessel is then reabsorbed by the body or becomes a fibrous cord. This procedure is used to treat varicose veins, spider veins, and other vascular malformations by eliminating the abnormal vessel without surgical removal.
Approved indications
- Varicose veins
- Spider veins (telangiectasia)
- Venous malformations
Common side effects
- Injection site pain or discomfort
- Bruising or hematoma at injection site
- Hyperpigmentation or skin discoloration
- Allergic reaction
- Thrombophlebitis
Key clinical trials
- Doxycycline Use in Post-Operative Seromas (PHASE2)
- Comparison of Outcome of Injection Sclerotherapy Versus Rubber Band Ligation for Second Degree Hemorrhoids (NA)
- Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose Veins (NA)
- Genicular Embolization Using Doxycycline Sclerotherapy (PHASE2)
- Systematic Approach for Children With Orbital Malformation With Sirolimus Use (PHASE3)
- Comparative Study Between Sclerosing Agents Used in Treatment of Vascular Malformation (NA)
- Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations (PHASE2)
- Polidocanol Foam With or Without Transdermal Laser for Varicose Veins: Randomized Clinical Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injection Sclerotherapy CI brief — competitive landscape report
- Injection Sclerotherapy updates RSS · CI watch RSS
- Gulab Devi Hospital portfolio CI